Company
Information

Directors

  • Roger H. Kimmel 1,3,4,5
    Chairman of the Board
    Vice Chairman, Rothschild Inc.
  • Paul V. Campanelli
    President and Chief Executive Officer
  • Shane M. Cooke 1,4
    President, Alkermes
  • Nancy J. Hutson, Ph.D. 3,4,5
    Retired Senior Vice President, Pfizer Global Research and Development
  • Michael Hyatt 2,3,4
    Senior Advisor, Irving Place Capital
  • Douglas S. Ingram 2,5
    Former Chief Executive Officer and Director, Chase Pharmaceuticals Corporation
  • William P. Montague 1,2,3,4
    Retired Chief Executive Officer and Director, Mark IV Industries, Inc.
  • Todd B. Sisitsky 3,4
    Partner, TPG
  • Jill D. Smith 1,3,5
    Former Chairman, Chief Executive Officer and President, DigitalGlobe Inc.
  • William F. Spengler 1,2,5
    Former President, ChromaDex Corporation

Executive Officers*

  • Paul V. Campanelli
    President and Chief Executive Officer
  • Blaise Coleman
    Executive Vice President and Chief Financial Officer
  • Terrance J. Coughlin
    Executive Vice President and Chief Operating Officer
  • Matthew J. Maletta
    Executive Vice President and Chief Legal Officer
  • Antonio R. Pera
    President, Par Pharmaceutical
  • Daniel A. Rudio
    Senior Vice President, Controller and Chief Accounting Officer
shape-4 shape-4

Senior Leadership

shape-4 shape-4
  • Joseph A. Barbarite
    Executive Vice President, Global Quality and Compliance
  • Patrick Barry
    Senior Vice President, U.S. Branded Pharmaceuticals
  • Mark Bradley
    Senior Vice President, Corporate Development
  • Lawrence A. Cunningham
    Executive Vice President, Human Resources
  • Jennifer E. Dubas
    Senior Vice President and Chief Compliance Officer
  • Rahul Garella
    Senior Vice President, Head of International Pharmaceuticals
  • Stephen Mock
    Senior Vice President, Investor Relations & Corporate Affairs
  • Brandon Rockwell
    Vice President, Business Development
  • Company Secretary

    Orla Dunlea
    International Legal Counsel and Company Secretary

Company Information

  • Auditors

    PricewaterhouseCoopers LLP
    Two Commerce Square,
    Suite 1700
    2001 Market Street
    Philadelphia, PA 19103-7045

  • Transfer Agent

    Computershare
    P.O. Box 43001
    Providence, RI 02940

    250 Royall Street
    Canton, MA 02021

  • Annual Shareholder Meeting

    Thursday, June 8, 2017 at 8:00 a.m.
    Irish Standard Time (IST)

    First Floor
    Minerva House
    Simmonscourt Road
    Ballsbridge
    Dublin 4
    Ireland

  • Corporate Counsel

    A&L Goodbody
    IFSC
    North Wall Quay
    Dublin 1
    Ireland

    Skadden, Arps, Slate,
    Meagher & Flom LLP
    4 Times Square
    New York, NY 10036

  • Investor Relations

    Stephen Mock
    Senior Vice President,
    Investor Relations and Corporate Affairs
    +1 845 364 4833

Stock Exchange

Endo common stock is listed on the NASDAQ Global Select Market under the ticker symbol ENDP. Note: NASDAQ quotes are in USD$.

shape-5

SEC Form 10-K

shape-5

A copy of the company's annual report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC), is available on our company website or may be obtained without charge by writing to:

First Floor
Minerva House
Simmonscourt Road
Ballsbridge
Dublin 4
Ireland


Caution: Forward-looking Statements

This document contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive, market and regulatory factors. More information about those factors is contained in Endo's filings with the U.S. Securities and Exchange Commission.

BELBUCA™ is a trademark of BioDelivery Sciences International, Inc. All other trademarks are trademarks of Endo International plc affiliates.